ENS platform presentation: alemtuzumab vs. IFNbeta-1a

Disease activity free status on Alemtuzumab vs. IFNbeta-1a (CAREMS 1 Study)
View more presentations from gavingiovannoni.
"My slides from my presentation at the European Neurological Society Meeting in Prague. The analysis shows that alemtuzumab is more effective than interferon-beta-1a (Rebif) in rendering someone  with active MS free of disease activity using clinical and MRI markers of disease activity."

CoI: Multiple